Q32 Bio posts strong Phase 2 results for alopecia drug Bempikibart

Q32 Bio (NASDAQ: QTTB) announced positive top‑line data from Part B of its SIGNAL‑AA Phase 2a trial of the experimental antibody Bempikibart in patients with severe or very severe alopecia areata. In the modified intent‑to‑treat population the treatment produced a 35.3% mean reduction in SALT score over 36 weeks, with 40% of patients achieving the SALT‑20 endpoint (≤20 % scalp hair loss). The overall intent‑to‑treat group showed a 30.3% SALT‑20 response. The drug was well tolerated; no Grade 3 or higher adverse events were reported and the most common side effect was mild injection‑site reactions in about 36 % of participants.

Following the data release Q32 Bio’s share price surged roughly 90%, closing at $21.38, and the company launched an underwritten public offering of $200 million of common stock to fund further development. The results are being positioned as a potential new standard for biologic treatment of alopecia, challenging existing JAK‑inhibitor therapies.